INT156351

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.51
First Reported 2008
Last Reported 2011
Negated 2
Speculated 0
Reported most in Body
Documents 22
Total Number 23
Disease Relevance 20.05
Pain Relevance 0.91

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Flt1) endosome (Flt1) Golgi apparatus (Flt1)
plasma membrane (Flt1) nucleus (Flt1) kinase activity (Flt1)
Anatomy Link Frequency
hearts 2
plasma 1
endothelial cells 1
blood vessel 1
HGF 1
Flt1 (Mus musculus)
Pain Link Frequency Relevance Heat
antagonist 17 94.28 High High
fibrosis 1 86.24 High High
rheumatoid arthritis 57 84.48 Quite High
aspirin 90 81.24 Quite High
Arthritis 8 79.20 Quite High
metalloproteinase 40 78.40 Quite High
cva 13 78.28 Quite High
Pain 2 73.04 Quite High
ischemia 9 67.32 Quite High
Inflammation 51 61.80 Quite High
Disease Link Frequency Relevance Heat
Fibromyalgia 23 100.00 Very High Very High Very High
Pre-eclampsia 1460 99.80 Very High Very High Very High
Pancreatic Cancer 57 99.68 Very High Very High Very High
Hypertrophy 53 99.24 Very High Very High Very High
Sickle Cell Anemia 6 99.00 Very High Very High Very High
Pressure And Volume Under Development 40 98.54 Very High Very High Very High
Adult Respiratory Distress Syndrome 28 98.32 Very High Very High Very High
Hypoxia 128 97.92 Very High Very High Very High
Solid Tumor 10 97.44 Very High Very High Very High
Cancer 218 96.76 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In general, the patterns of angiogenic factor concentrations across pregnancy in this study (i.e. elevated sFlt1 and sEng and low PlGF among subjects who develop preeclampsia) are similar to those presented in studies of low-risk pregnant women.
Positive_regulation (elevated) of sFlt1 associated with pre-eclampsia
1) Confidence 0.51 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2952583 Disease Relevance 0.58 Pain Relevance 0
Increased levels of soluble VEGFR-1(s-flt) have been demonstrated to contribute to these observations (23).
Positive_regulation (Increased) of s-flt
2) Confidence 0.45 Published 2010 Journal American Journal of Physiology - Lung Cellular and Molecular Physiology Section Body Doc Link PMC2886605 Disease Relevance 0.71 Pain Relevance 0.04
In most cases, however, even when the differences are not significant, the relationship of mean values of these angiogenic factors is similar to that observed in low-risk women with higher sFlt1 and sEng and lower PlGF in women who later develop preeclampsia suggesting these factors may play a role in the pathophysiology of preeclampsia in these high-risk groups.
Positive_regulation (higher) of sFlt1 associated with pre-eclampsia
3) Confidence 0.42 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2952583 Disease Relevance 0.78 Pain Relevance 0
The pattern of elevated concentrations of sFlt1 and sEng, and low PlGF in high-risk pregnant subjects who develop preeclampsia is similar to that reported in low-risk pregnant women.
Positive_regulation (elevated) of sFlt1 associated with pre-eclampsia
4) Confidence 0.39 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2952583 Disease Relevance 0.92 Pain Relevance 0.03
The odds of developing preeclampsia were significantly increased for each 2-fold elevation in sFlt1, sEng and the angiogenic factor ratio, and were significantly decreased for each 2-fold elevation in PlGF at study entry in subjects with multifetal gestations.
Positive_regulation (elevation) of sFlt1 associated with pre-eclampsia
5) Confidence 0.39 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2952583 Disease Relevance 0.68 Pain Relevance 0
The odds of developing preeclampsia were significantly increased among women with multiple fetuses for each 2-fold elevation in sFlt1, sEng and the ratio of angiogenic factors (e.g.
Positive_regulation (elevation) of sFlt1 associated with pre-eclampsia
6) Confidence 0.39 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2952583 Disease Relevance 0.92 Pain Relevance 0.04
A study by the same group also reported that maternal serum sFlt1 and PlGF are significantly elevated in subjects with multifetal gestations as early as 22 weeks' gestation [15].
Positive_regulation (elevated) of sFlt1
7) Confidence 0.39 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2952583 Disease Relevance 0.79 Pain Relevance 0
Maternal sFlt1 was significantly elevated 2 to 5 weeks before the onset of preeclampsia in the subjects with previous preeclampsia, as well as within 1 week of the clinical onset of preeclampsia (Figure 4D).
Positive_regulation (elevated) of sFlt1 associated with pre-eclampsia
8) Confidence 0.37 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2952583 Disease Relevance 1.30 Pain Relevance 0
Among low-risk pregnant patients, sFlt1 has been reported to be significantly elevated by 33 to 36 weeks' gestation and >5 weeks before the clinical onset of preeclampsia [10].
Positive_regulation (elevated) of sFlt1 associated with pre-eclampsia
9) Confidence 0.34 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2952583 Disease Relevance 0.86 Pain Relevance 0
However, sFlt1 concentrations were not significantly elevated before the onset of preeclampsia in any of the other high-risk groups (Figures 4A, B and C).
Neg (not) Positive_regulation (elevated) of sFlt1 associated with pre-eclampsia
10) Confidence 0.34 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2952583 Disease Relevance 1.28 Pain Relevance 0
Other agents which target VEGF receptors, such as, chimerized anti-KDR antibody, VEGF-Trap, and a synthetic ribozyme of Flt-1, are also undergoing phase I or II trials for the treatment of solid tumors and cancer [36].
Positive_regulation (ribozyme) of Flt-1 associated with cancer and solid tumor
11) Confidence 0.32 Published 2008 Journal Mediators of Inflammation Section Body Doc Link PMC2638142 Disease Relevance 1.43 Pain Relevance 0.31
These investigators observed increases in placental soluble fms-like tyrosine kinase 1 (sFlt1) in preeclampsia patients accompanied by decreases in circulating VEGF, and placental growth factor (PlGF).
Positive_regulation (increases) of sFlt1 associated with fibromyalgia and pre-eclampsia
12) Confidence 0.31 Published 2011 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC3005972 Disease Relevance 1.39 Pain Relevance 0.04
The authors concluded that elevated and excessive levels of circulating sFlt1 are a major contributor to the pathogenesis of preeclampsia.
Positive_regulation (elevated) of sFlt1 associated with pre-eclampsia
13) Confidence 0.31 Published 2011 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC3005972 Disease Relevance 1.09 Pain Relevance 0.05
The growth of blood vessels (angiogenesis) is primarily initiated by activation of VEGFR-1 and VEGFR-2 by VEGF-A, whereas lymphangiogenesis is predominantly driven by VEGF-C, which activates VEGFR-2 and VEGFR-3 expressed in lymphatic endothelial cells.
Positive_regulation (activation) of VEGFR-1 in endothelial cells
14) Confidence 0.22 Published 2010 Journal BMC Med Section Body Doc Link PMC2989928 Disease Relevance 1.22 Pain Relevance 0
Differential expression of isoforms of the transcription factor HIF and the subsequent induction of target genes such as VEGFR-1 and VEGFR-2 appear responsible for the response to hypoxia in hypertrophied hearts.
Positive_regulation (induction) of VEGFR-1 in hearts associated with hypoxia
15) Confidence 0.17 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2603310 Disease Relevance 1.10 Pain Relevance 0.03
Bevacizumab binds directly to all VEGF-A isoforms which suppresses activation of its receptors 1 (Flt-1) and 2 (KDR) on the surface of endothelial cells.13 This neutralization of the ligand–receptor interaction results in inhibition of endothelial cell proliferation and new blood vessel formation.
Positive_regulation (activation) of Flt-1 in blood vessel
16) Confidence 0.16 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2962304 Disease Relevance 0.60 Pain Relevance 0
In sham-operated normoxic hearts, very little VEGF receptor-1 protein was detected, and there was apparently no increase in VEGFR-1 protein in response to LV hypertrophy alone.
Neg (no) Positive_regulation (increase) of VEGFR-1 protein in hearts associated with hypertrophy
17) Confidence 0.16 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2603310 Disease Relevance 0.84 Pain Relevance 0
Thus, our results suggest that MUC5AC positive pancreatic cancer cells might be activated the invasive potential via VEGFR-1 signaling pathway in an autocrine manner.
Positive_regulation (activated) of VEGFR-1 associated with pancreatic cancer
18) Confidence 0.11 Published 2010 Journal J Exp Clin Cancer Res Section Body Doc Link PMC2893453 Disease Relevance 0.80 Pain Relevance 0.10
VEGF-A induced signaling cascade is mediated via activation of both of VEGFR-1 and VEGFR-2.
Positive_regulation (activation) of VEGFR-1
19) Confidence 0.10 Published 2010 Journal J Exp Clin Cancer Res Section Body Doc Link PMC2893453 Disease Relevance 0.67 Pain Relevance 0.19
We previously demonstrated a severe angiogenic imbalance in DBA/2 mated CBA/J mice, characterized by increased plasma sFlt-1 levels and low free VEGF levels [5].
Positive_regulation (increased) of sFlt-1 in plasma
20) Confidence 0.10 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2965104 Disease Relevance 0.27 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox